首页> 美国卫生研究院文献>Drug Design Development and Therapy >Laquinimod Protects Against TNF-α-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2
【2h】

Laquinimod Protects Against TNF-α-Induced Attachment of Monocytes to Human Aortic Endothelial Cells (HAECs) by Increasing the Expression of KLF2

机译:拉喹莫德可通过增加KLF2的表达来防止TNF-α诱导的单核细胞附着于人主动脉内皮细胞(HAEC)。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As a worldwide health issue, the treatment and prevention of atherosclerosis present an important goal. Increased levels of proinflammatory cytokines such as TNF-α-associated chronic inflammatory response cause endothelial cells to lose their ability to regulate vascular function. Lipid-laden immune cells are recruited to the endothelium where they adhere to the endothelial wall and invade the intimal space, thereby leading to the development of atherosclerotic lesions, fatty plaques, and thickening of the arterial wall. In the present study, for the first time, we investigated the effects of laquinimod, an immunomodulatory agent used for the treatment of multiple sclerosis, on human aortic endothelial in a TNF-α-induced atherosclerotic microenvironment. At present, the mechanism of action of laquinimod is not well defined.
机译:作为全球性的健康问题,动脉粥样硬化的治疗和预防是一个重要的目标。促炎细胞因子(如与TNF-α相关的慢性炎症反应)水平升高,导致内皮细胞失去调节血管功能的能力。携带脂质的免疫细胞被募集到内皮细胞,在那里它们粘附于内皮壁并侵入内膜空间,从而导致动脉粥样硬化病变,脂肪斑块的形成以及动脉壁的增厚。在本研究中,我们首次研究了用于治疗多发性硬化症的免疫调节剂拉喹莫德对人主动脉内皮细胞在TNF-α诱导的动脉粥样硬化微环境中的作用。目前,拉喹莫德的作用机理尚不明确。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号